Avenue Therapeutics, Inc.

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

https://www.avenuetx.com

ATXI United States

8.47USD1.61 (-19.01%)

• At close Wed Oct 05 2022

NasdaqCM exchange

Sector: Healthcare

Industry: Biotechnology

Location United States, New York

Grade: AFF

6,404,222 USD
MARKET CAP
.
PE
-0.249
BETA (5y)
-0.312
EPS

Profits

for 5 years
125%
for 3 years
-13%
for 2 years
43%
for last year
1,059%
for this year
0%
Avenue Therapeutics, Inc.
© 2023 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.